title: Loss of CD38 correlates with simultaneous up-regulation of human leukocyte antigen-DR in benign prostatic glands, but not in fetal or androgen-ablated glands, and is strongly related to gland atrophy.
abstract: OBJECTIVE
  To determine whether CD38 loss in benign and malignant prostatic disease is related to human leukocyte antigen (HLA)-DR up-regulation, by assessing the histopathology of the prostate and the effect of androgen deprivation.
  
  
  METHODS
  Serial sections of frozen fetal (eight), infant (six), normal adult (10), benign hyperplastic (BPH, 24), and primary (10) and hormone-treated (11) carcinomatous human prostatic tissues were analysed by immunohistology for anti-CD38 and HLA-DR antigens.
  
  
  RESULTS
  In BPH samples there was a significant correlation between CD38 loss (mean 21% of acini) and HLA-DR up-regulation (mean 20%; P < 0.001). Moreover, 76% of all CD38-negative acini in BPH had HLA-DR up-regulation in the same prostate epithelial cells, predominantly in atrophic and cystic glands, and in cells with retained secretions (74%). In contrast to the uniform expression in normal adult prostate, CD38 was negative or partly expressed in fetal acini (mean 19%) and almost completely negative in acini of the early infant period (mean 0.7%). In contrast to BPH, cancer cells did not selectively up-regulate HLA-DR when CD38 was lost. In patients with cancer treated by androgen deprivation, cancer cells were CD38-negative.
  
  
  CONCLUSIONS
  The absence of CD38 and presence of HLA-DR expression in prostatic epithelium is consistent in BPH and tissue surrounding tumour, and strongly related to gland atrophy. This is particularly interesting as HLA-DR triggering can induce apoptosis of cells, whereas CD38 prevents it. A permissive role for androgens to maintain full CD38 expression in epithelial cells is suggested.
authors.affiliation: Department of Urology, University of Vienna, Austria. gero_kramer@hotmail.com
authors.forename: G
authors.initials: G
authors.lastname: Kramer
authors.forename: G E
authors.initials: GE
authors.lastname: Steiner
authors.forename: P
authors.initials: P
authors.lastname: Sokol
authors.forename: R
authors.initials: R
authors.lastname: Mallone
authors.forename: G
authors.initials: G
authors.lastname: Amann
authors.forename: M
authors.initials: M
authors.lastname: Marberger
mesh_terms: D036541:ADP-ribosyl Cyclase / Q000378:metabolism*; D051997:ADP-ribosyl Cyclase 1; D000293:Adolescent; D000328:Adult; D000728:Androgens / Q000378:metabolism; D015703:Antigens, CD / Q000378:metabolism*; D001284:Atrophy / Q000378:metabolism; D002648:Child; D002675:Child, Preschool; D006680:HLA Antigens / Q000378:metabolism*; D006801:Humans; D015151:Immunoblotting; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008562:Membrane Glycoproteins; D011467:Prostate / Q000196:embryology* / Q000473:pathology; D011470:Prostatic Hyperplasia / Q000276:immunology*; D011472:Prostatitis / Q000378:metabolism; D015854:Up-Regulation
chemical_list: D000728:Androgens; D015703:Antigens, CD; D006680:HLA Antigens; D008562:Membrane Glycoproteins; D036541:ADP-ribosyl Cyclase; C498154:CD38 protein, human; D051997:ADP-ribosyl Cyclase 1